Red cell alloimmunisation in oncology patients: A study from eastern India

Area of Science:

• Transfusion Medicine
• Oncohematology
• Immunology

Background:

• Red cell alloimmunisation is a significant complication in patients receiving multiple transfusions for hematologic and surgical malignancies.
• Ensuring transfusion safety necessitates antibody screening and identification, yet data on alloimmunisation prevalence in oncology patients is scarce.
• This study aimed to evaluate red cell alloimmunisation in multi-transfused oncology patients.

Purpose of the Study:

• To assess the prevalence of red cell alloimmunisation in multi-transfused haematology-oncology patients.
• To determine the specificity of identified antibodies.
• To evaluate the necessity of repeated antibody screening post-transfusion.

Main Methods:

• A retrospective analysis of antibody screening data was conducted for haematopoietic stem cell transplant (HSCT) and surgical oncology patients between April 2013 and May 2014.
• Antibody screening utilized a three-cell panel (Surgiscreen), with positive results further investigated using an 11-cell panel (Resolve Panel A).
• Patients with autoantibodies, identified via autocontrol testing, were excluded.

Main Results:

• The overall red cell alloimmunisation rate was found to be 2.5%.
• The alloimmunisation rate was 1.6% in HSCT patients and 2.4% in patients with solid organ malignancies.
• The study identified specific alloantibody specificities, though not detailed in the abstract.

Conclusions:

• The overall alloimmunisation rate in this cohort of oncology patients is relatively low.
• The alloimmunisation rates in HSCT and solid organ malignancy patients were 1.6% and 2.4%, respectively.
• The findings question the routine justification for repeating antibody screening 72 hours post-transfusion in these patients.